What happened

Shares of Exact Sciences (NASDAQ:EXAS) were soaring 12% as of 10:49 a.m. EST on Monday. The big jump came after the diagnostics company announced preliminary fourth-quarter results on Sunday evening.

So what

With such an impressive gain today, it's not surprising that Exact Sciences' preliminary results looked really good. The company expects to post fourth-quarter revenue between $464.5 million and $467.5 million. The low end of that range is well above the consensus analysts' estimate of $431.2 million.

The biggest chunk of the company's revenue will come from screening, which includes its Cologuard and Biomatrica products. Exact Sciences projects screening revenue in the fourth quarter will increase 9% year over year to a range of $249 million to $250 million. Precision oncology revenue generated by the Oncotype cancer diagnostics test is anticipated to come in between $117 million and $118 million. The company also looks for another big boost from COVID-19 testing, with fourth-quarter revenue between $98.5 million and $99.5 million.

As you might expect, Exact Sciences' tremendous quarterly performance should also make its full-year 2021 numbers even better. The company now expects total revenue for the year to be between $1.49 billion and $1.493 billion. The average analyst estimate projected full-year revenue of $1.46 billion.

Now what

These aren't final numbers. Exact Sciences still hasn't finished preparing its financial statements for the fourth quarter or full-year 2020. The company plans to conduct its quarterly earnings call in February. There's no question, though, that the prospects for the healthcare stock continue to look bright.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.